New Nicholas, Mohandas Janaki, John George T, Ratanjee Sharad, Healy Helen, Francis Leo, Ranganathan Dwarakanathan
Department of Nephrology, Royal Brisbane and Women's Hospital, Queensland Health, Butterfield Street, Herston, QLD 4029, Australia.
Int J Nephrol. 2011;2011:982854. doi: 10.4061/2011/982854. Epub 2011 Jun 27.
Calciphylaxis or calcific uremic arteriolopathy is an infrequent complication of end stage kidney disease. It is characterized by arteriolar medial calcification, thrombotic cutaneous ischemia, tissue necrosis often leading to ulceration, secondary infection and increased mortality rates. Current, multimodality treatment involves local wound care, well-controlled calcium, phosphate and parathyroid hormone levels and combination therapy with sodium thiosulfate and hyperbaric oxygen therapy. This combination therapy may be changing the historically poor prognosis of calcific uremic arteriolopathy reported in the literature. Peritoneal dialysis is considered a risk factor based on limited publications, however this remains to be proven. Clinical presentation, diagnosis, pathogenesis and treatment of calcific uremic arteriolopathy in these patients are no different from other patients manifesting with this condition.
钙化防御或钙化性尿毒症小动脉病是终末期肾病的一种罕见并发症。其特征为小动脉中层钙化、血栓性皮肤缺血、常导致溃疡的组织坏死、继发感染及死亡率增加。目前,多模式治疗包括局部伤口护理、严格控制钙、磷及甲状旁腺激素水平,以及硫代硫酸钠与高压氧疗法的联合治疗。这种联合治疗可能正在改变文献中报道的钙化性尿毒症小动脉病历来较差的预后。基于有限的出版物,腹膜透析被认为是一个危险因素,然而这仍有待证实。这些患者中钙化性尿毒症小动脉病的临床表现、诊断、发病机制及治疗与表现出该病症的其他患者并无不同。